Monitoring tumor response to therapy with 18F-FLT PET

Journal of Nuclear Medicine

Volumn 51, Issue 6, 2010, Pages 841-844

  Weber, Wolfgang A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; GEFITINIB; IRINOTECAN; KI 67 ANTIGEN; RITUXIMAB; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

BRAIN CANCER; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FALSE POSITIVE RESULT; GERM CELL TUMOR; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECTUM CANCER; REVIEW; SEMINOMA; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; ANIMAL; NEOPLASM; NOTE; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOLOGY; SCINTISCANNING; TREATMENT OUTCOME;

ANIMALS; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASTIC PROCESSES; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 77953954736     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.071217     Document Type: Review

References (31)

1. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
2. 18F-FDG. J Nucl Med. 2003;44:1426-1431.
3. 18F- fluorodeoxyglucose-positron emission tomography. Chest. 2006;129:393-401.
4. 18F-FDG PET in esophageal cancer. J Nucl Med. 2005;46:400-404.
5. 18F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2008;35:236-245.
6. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med. 2007;48:726-735.
7. 18F- 3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer? J Nucl Med. 2004;45:1677-1682.
8. 18F]fluoro-2- deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging. 2003;30:988-994.
9. 3H- fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006;12:4590-4597.
10. 18F] fluoro-3'-deoxythymidine (FLT). Mol Imaging Biol. 2007;9:340-347.
11. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
12. 18F] fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005;65:4202-4210.
13. 18F- fluorothymidine PET. J Nucl Med. 2005;46:114-120.
14. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA. Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res. 2008;14:3416-3426.
15. Ullrich RT, Zander T, Neumaier B, et al. Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One. 2008;3:e3908.
16. 18F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med. 2009;50:1102-1109.
17. 18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res. 2008;14:4463-4468.
18. 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging. 2009;36:389-395.
19. 18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721.
20. Pio BS, Park CK, Pietras R, et al. Usefulness of 3'-[F-18]fluoro-3'- deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42.
21. 18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-1347.
22. 18F]fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res. 2008;14:7423-7429.
23. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-3558.
24. Kheirallah S, Caron P, Gross E, et al. Rituximab inhibits B-cell receptor signaling. Blood. 2010;115:985-994.
25. 18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878-883.
26. 18F-FLT positron emission tomography/computed tomography imaging for nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75:1098-1104.
27. 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med. 2010;51:845-853.
28. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA. 2008;299:672-684.
29. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22:1034-1039.
30. 18F] fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol. 2008;26:5930-5935.
31. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.